Vasa in Ayurveda: Properties & Everyday Use

What it is

Vasa is the dried leaf of Adhatoda vasica Nees (syn. Justicia adhatoda L.), an evergreen shrub of the family Acanthaceae native to the Indian subcontinent. "Vasa" is the classical Sanskrit drug name; "vasaka" is the common name for the same plant: this article is the classical monograph, while our companion article on vasaka covers the plant's pharmaceutical afterlife (the cough drugs bromhexine and ambroxol were developed from its alkaloid vasicine). A review of vasapatra (vasa leaf) research confirms the leaf as the official drug material (IJPPR review of vasapatra research).

The principal bioactive compounds are the quinazoline alkaloids vasicine and vasicinone, concentrated in the leaves (IJPPR review of vasapatra research). The leaf has a long history of use in the Ayurvedic and Unani medicine systems of India (IJRAR 2024 review).

Classical properties

• Taste (rasa): bitter (Tikta), astringent (Kashaya)
• Qualities (guna): light (Laghu)
• Potency (virya): cooling (Sheeta)
• After digestion (vipaka): pungent (Katu)
• Doshas: traditionally said to settle Pitta; may increase Vata

Traditional use

Classical texts describe vasa above all for the chest: cough, asthma, chronic bronchitis, and as an expectorant for excess phlegm, with additional folk uses recorded for menorrhagia (heavy menstrual bleeding), bleeding hemorrhoids, tuberculosis, fever, and wound-related complaints (traditional-uses survey, IJRAR 2024 review). These are traditional descriptions, not clinical proof; what human research shows is examined below.

What research has looked at

The human evidence is thin

Human evidence for the herb itself is thin. Our companion article on vasaka summarizes the available clinical material: small trials in asthma and bronchitis, some with comparison groups and random assignment, that reported symptom improvement, but too limited in size and rigor to establish efficacy. This article does not repeat those trials; see the vasaka article for the clinical detail.

Toxicology and pharmacology

The best-documented modern science on vasa concerns its toxicity profile rather than its efficacy:

• Wakhloo et al. (1980) tested pure vasicine in 24 postpartum inpatients, administered intravenously in saline. The compound was tolerated with no undesirable effects on clinical observations, hematology, or liver and kidney function: but the uterus became firm and contracted after treatment, confirming vasicine's effectiveness as an oxytocic with abortifacient potential (reviewed in the IJPPR vasapatra review).
• Pahwa et al. (1987) conducted a 6-month chronic toxicity study of Adhatoda vasica in rats and monkeys: no change in mortality or body weight, and autopsy plus histology of major organs revealed no abnormality (same review).
• In animals, leaf extracts were found 100% abortive at the doses tested in one experimental study: though one other study did not reproduce an abortifacient effect, so the animal literature is not unanimous (same review).

European regulators have acted on exactly this concern: the European Medicines Agency's herbal committee (HMPC) concluded that a Community herbal monograph on Adhatoda vasica leaf cannot be established unless additional information becomes available, citing reproductive-safety concerns and insufficient traditional-use data (EMA/HMPC/681468/2012) (HMPC public statement, via mirror of draft statement).

What the evidence does not support (yet)

There are no large, well-controlled human trials establishing that vasa leaf relieves cough, asthma, or bronchitis, or that it treats bleeding disorders. The respiratory reputation is pharmacologically plausible, vasicine's semi-synthetic derivatives became proven cough medicines, but plausibility is not proof for the leaf itself. The detailed trial picture is in our vasaka article.

Safety notes

The single clearest safety signal is reproductive. Vasicine is oxytocic: it contracts the uterus, as shown when intravenous vasicine made the uterus firm and contracted in 24 postpartum inpatients (IJPPR vasapatra review). Vasa should be avoided in pregnancy (HMPC public statement, via mirror of draft statement). The European HMPC declined to establish a monograph for the leaf on reproductive-safety grounds. Beyond pregnancy, dedicated long-term safety data in humans are lacking; a 6-month animal chronic-toxicity study showed no organ abnormalities at the tested doses, but that does not substitute for human data. Because of the uterine effects, it should also be avoided when trying to conceive and during breastfeeding unless a qualified practitioner advises otherwise.

FAQs

What is the difference between vasa and vasaka?

None botanically: both are the classical and common names for Adhatoda vasica leaf. This article is the classical "Vasa" monograph (identity, traditional indications, toxicology); our companion vasaka article focuses on the pharmaceutical story (bromhexine and ambroxol were developed from vasicine) and the small clinical trials.

Is vasa proven to work for cough or asthma?

No. The human evidence consists of small trials reporting symptom improvement, but they were too limited in size and rigor to prove efficacy. The respiratory use is pharmacologically plausible (vasicine's derivatives became real cough drugs), but the leaf itself has not been validated in rigorous trials.

Is vasa safe in pregnancy?

No: it should be avoided. Vasicine is oxytocic: intravenous vasicine caused the uterus to contract in postpartum inpatients (IJPPR vasapatra review), and the European HMPC refused a monograph for the leaf on reproductive-safety grounds (EMA/HMPC/681468/2012).

What is vasicine?

Vasicine is the principal quinazoline alkaloid of vasa leaves (with vasicinone as its oxidation product). It was the starting compound for developing the mucolytic drugs bromhexine and ambroxol, and it is the compound responsible for vasa's uterine-contracting effects (IJPPR vasapatra review).

What is the recommended dose of vasa?

Swastik does not suggest amounts. The right amount depends on the person, the preparation and the product, so check with a qualified Ayurvedic practitioner or your doctor before taking any herb.

Sources

• Claeson UP, Malmfors T, Wikman G, Bruhn JG. "Adhatoda vasica: a critical review of ethnopharmacological and toxicological data." Journal of Ethnopharmacology. 2000;72(1–2):1–20. DOI: 10.1016/S0378-8741(00)00225-7 — DOI · 10.1016/S0378-8741(00)00225-7
• "Review on Research Studies of Vasapatra (Leaf of Adhatoda vasica Nees.)" — Int. J. Pharmacognosy (IJPPR), full text — ijpjournal.com
• European Medicines Agency / HMPC. "Public statement on Adhatoda vasica Nees, folium" (EMA/HMPC/681468/2012) — imedi.co.uk (mirror of the draft public statement; official document reference EMA/HMPC/681468/2012)
• "A review on pharmacological activity and traditional uses of Adhatoda vasica." IJRAR. 2024;11(1) — ijrar.org
• Swastik companion article: Vasaka — Swastik

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.